Barclays Double Downgrades Janux Therapeutics (JANX) to Underweight

April 20, 2026 3:59 AM

Barclays analyst Etzer Darout downgraded Janux Therapeutics (NASDAQ: JANX) from Overweight to Underweight with a price target of $14.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found